Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06321341
Status:
RECRUITING
Last Update Posted:
2024-03-20
First Post:
2024-03-13
Brief Title:
Efficacy and Safety of Vespireit Sustained-release Tablets in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo
Sponsor:
Valenta Pharm JSC
Organization:
Valenta Pharm JSC
Study Overview
Official Title:
Open Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Vespireit Prolonged-release Tablets Valenta Pharm JSC Russia and Arlevert Tablets Menarini International Operations Luxembourg SA Luxembourg in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study of efficacy and safety of Vespireit prolonged-release tablets 15 mg Valenta Pharm JSC Russia in comparison with Arlevert tablets 40 mg 20 mg Menarini International Operations Luxembourg SA Luxembourg in patients with autonomic dysfunction syndrome accompanied by functional vertigo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None